TheraPsil Seeks Permission From Health Canada to Use Psilocybin Treatments for Dying Patients
Bruce Tobin is asking Health Canada to approve psilocybin to treat anxiety and depression in end-of-life patients.
Health - Page 17
Analysis of the Future Psilocybin Pharmaceutical Market
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.
Psilocybin For Smoking Cessation Works Via Drug and Non-Drug Factors
Psilocybin-assisted therapy is showing promise for quitting smoking, but how does it work?
Research and Development of 5-HT3 Agonist Drugs
Pharma companies with expertise in 5-HT3 receptors are focusing on antagonist drugs to combat nausea and vomiting in chemotherapy patients.
Study Compares the Effects of Psilocybin and DXM
Psilocybin produces more insightful and mystical experiences, but dextromethorphan causes greater feelings of disembodiment.
Johns Hopkins Researchers Call for Rescheduling Psilocybin
Researchers push to move psilocybin from Schedule I to Schedule IV if Phase III clinical trials are successful.
Psilocin Promotes Structural and Functional Neuroplasticity
Psilocin makes neurons grow faster and produce more connections.
Australian Hospital to Dose Dying Patients with Synthetic Psilocybin
St Vincent's Hospital of Melbourne, Australia will begin treating patients in April
Psilocybin Receives FDA Breakthrough Treatment Designation
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.
Psilocybin for Treating Phantom Pain
Psilocybin is showing promise for neuroregeneration and motor recovery in methods of treating phantom pain.